Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jan
29
2015
Supreme Court Holds Claim Construction Facts Are Subject to Clear Error Review Honigman Miller Schwartz and Cohn LLP
Dec
20
2014
Myriad's Breast Cancer Test Patents Not Patent Eligible Honigman Miller Schwartz and Cohn LLP
Oct
7
2015
Dunkin’ Donuts: Your Munchkin Is Showing IMS Legal Strategies
Dec
21
2017
Compounders Who Skirt The FDA: Who Is The Expert Here? IMS Legal Strategies
Jun
25
2019
Episode 2: The Future of STEM and Aerospace Engineering [Podcast] IMS Legal Strategies
May
19
2022
Expert Witness Case Complexity & Vetting – Episode 36 [Podcast] IMS Legal Strategies
Dec
1
2022
Chemical Engineering Trends, Intellectual Property Litigation, & Industry Predictions – Episode 50 [PODCAST] IMS Legal Strategies
Aug
14
2015
U.S. v. Bayer Is Proof ─ Daubert Is Not Hard To Digest IMS Legal Strategies
Mar
17
2017
Are Biosimilars Really That Similar? The $40B Question IMS Legal Strategies
Dec
30
2015
Getting Past Gatekeeper: “No Shoes, No Shirt, No Service” re: Admissibility of Expert Opinions IMS Legal Strategies
Aug
26
2015
Trademarking: Capri Sun Says “Respect the Pouch” IMS Legal Strategies
Oct
19
2016
Monopoly on Medical Marijuana? IMS Legal Strategies
Dec
4
2014
Court-Appointed Experts: The Future of Litigation? IMS Legal Strategies
Sep
4
2015
Wine Seller Victory in Illinois Qui Tam Lawsuit Horwood Marcus & Berk Chartered
Sep
14
2021
Marijuana Legalization Rundown: Recent Judicial Decisions Epstein Becker & Green, P.C.
Mar
1
2022
Unpacking Averages: Connecting Published Clinical Trials with FDA Drug Approvals Epstein Becker & Green, P.C.
Aug
26
2022
Will the Supreme Court’s Latest Decision on Mens Rea Leave Medical Professional Prosecutions Ruan-ing on Empty? Epstein Becker & Green, P.C.
Feb
9
2023
Podcast: Unpacking FDA’s Final Clinical Decision Support Guidance – Diagnosing Health Care [VIDEO] Epstein Becker & Green, P.C.
Mar
3
2023
FDA Issues Draft Guidance on Labeling of Plant-Based Milk Alternatives Epstein Becker & Green, P.C.
Dec
30
2019
California Puts a Foot On the Scale to Drive Unionization Higher: AB 1291 Mandates State-Sponsored Assistance in Organizing Cannabis Employees Epstein Becker & Green, P.C.
May
12
2020
New York Employers: Engage in the Interactive Process Before Disciplining Medical Marijuana Users Epstein Becker & Green, P.C.
Mar
25
2021
Merger Reviews Likely to Address More Expansive—and Possibly New—Theories of Harm Epstein Becker & Green, P.C.
Nov
7
2017
CMS Final Rule Will Reduce Medicare Part B Drug Payments by Nearly 30% for 340B Hospitals Epstein Becker & Green, P.C.
Aug
15
2018
Will Federal Special Registration Exception Preempt More Stringent State Rules on Remote Prescribing of Controlled Substances? Epstein Becker & Green, P.C.
Nov
1
2021
Unpacking Averages: Analyzing Descriptions from Cardiovascular Device Adverse Events Epstein Becker & Green, P.C.
Dec
1
2021
Unpacking Averages: Popular Ways to Combine Device Functionality Epstein Becker & Green, P.C.
Dec
20
2018
Marijuana Legalization Takes Another Step Forward in 2018 Elections Epstein Becker & Green, P.C.
Jan
25
2019
FDA Embraces Role in Managing Medical Device Cybersecurity Risk by Issuing New Guidance Epstein Becker & Green, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins